Tilo Grosser, MD

Research Assistant Professor of
Pharmacology

Member, Institute for Translational Medicine and Therapeutics

Contact Information:
809 Biomedical Research Building II/III
421 Curie Boulevard
Philadelphia, PA 19104
Office: 215-573-7600
Fax: 215-573-9004

 

 

 

 

 

 

 

 

Research Interest

Selected Publications

Email:

Non-steroidal anti-inflammatory drugs (NSAIDs), which include both traditional NSAIDs (e.g. naproxen, ibuprofen) and NSAIDs selective for cyclooxygenase (COX)-2 (rofecoxib, valdecoxib, etoricoxib, lumiracoxib, celecoxib) relieve pain, inflammation and fever by inhibiting the formation of bioactive prostanoids. Despite their efficacy in the relief of pain and inflammation, NSAIDs may be associated with gastrointestinal complications, including serious bleeds. Selectivity for COX-2 has been shown to reduce the incidence of these serious events, but is more likely to cause serious cardiovascular events than non-selective COX inhibition. We are studying the mechanisms of these complications using genomics, proteomics, lipidomics approaches in model organisms and in proof-of-concept studies in healthy volunteers. The aim of this research is to identify approaches to the individualization of NSAID therapy, which would allow to harvest the value of these drugs while reducing their risk.

Links

Empirical Bayes Identifier Project
A novel probability based analysis tool for complex shotgun proteomics datasets

ITMAT Zebrafish Proteomics Project
The zebrafish proteomics database

Clinical Studies

Proof-of-concept studies

 

 

 

Education:
MD (Medicine), Heinrich-Heine University, Düsseldorf, Germany 1996

 

In the Press

ITMAT Bioinformatics Facility

Clinical Translational Research Center

Clinical Study Volunteer Registration

Zebrafish Proteomics Database

Complete publication list                           

 

 

Search for articles

Lucitt MB, Price TS, Pizarro A, Wu W, Yocum AK, Seiler C, Pack MA, Blair IA, FitzGerald GA, Grosser T. Analysis of the zebrafish proteome during embryonic development. Molecular & Cellular Proteomics 7(5):981-94 (2008).

MCP’s May issue Cover Figure (download) 

Hahn CG, Banerjee A, Macdonald ML, Cho DS, Kamins J, Nie Z, Borgmann-Winter KE, Grosser T, Pizarro A, Ciccimaro E, Arnold SE, Wang HY, Blair IA. The post-synaptic density of human postmortem brain tissues: an experimental study paradigm for neuropsychiatric illnesses. PLoS One. 2009;4(4):e5251. Epub 2009 Apr 16.

PMID: 19370153

 

Marzoll A, Nagy N, Wördehoff L, Fries S, Lindner V, Grosser T, Fischer JW. Cyclooxygenase Inhibitors Repress Vascular Hyaluronan-Synthesis in Murine Atherosclerosis and Neointimal Thickening.

J Cell Mol Med. 2009 Mar 17. [Epub ahead of print] PMID: 19320776

 

Smyth EM, Grosser T, Wang M, Yu Y, FitzGerald GA. Prostanoids in health and disease. J Lipid Res. 2009 Apr;50 Suppl:S423-8. Epub 2008 Dec 17. Review. PMID: 19095631

 

Lucitt MB, Price TS, Pizarro A, Wu W, Yocum AK, Seiler C, Pack MA, Blair IA, FitzGerald GA, Grosser T. Analysis of the zebrafish proteome during embryonic development. Mol Cell Proteomics. 7(5):981-94 (2008).

MCP’s May issue Cover Figure (download).

 

Song WL, Wang M, Ricciotti E, Fries S, Yu Y, Grosser T, Reilly M, Lawson JA, FitzGerald GA.

Tetranor PGDM, an abundant urinary metabolite reflects biosynthesis of prostaglandin D2 in mice and humans.

J Biol Chem. 2008 Jan 11;283(2):1179-88.

 

Price TS, Lucitt MB, Wu W, Austin DJ, Pizarro A, Yocum AK, Blair IA, Fitzgerald GA, Grosser T. EBP: Protein identification using multiple tandem mass spectrometry datasets. Mol Cell Proteomics. 6(3):527-36, (2007).

 

North TE, Goessling W, Walkley CR, Lengerke C, Kopani KR, Lord AM, Weber G,  Jang IH, Grosser T, FitzGerald GA, Daley GQ, Orkin SH, Zon LI. Prostaglandin E2 Regulates Vertebrate Hematopoietic Stem Cell Homeostasis, Nature, 447(7147):1007-11 (2007).

 

Grosser T. The pharmacology of selective inhibition of COX-2. Thromb Haemost. 96(4):393-400 (2006).

 

Grosser T, Fries S, FitzGerald GA, Biological Basis for the Cardiovascular Consequences of COX-2 inhibition; Therapeutic Challenges and Opportunities, Journal of Clinical Investigation 116(1):4-15 (2006).

 

Fries S*, Grosser T* *[Co-Firstauthors], Lawson J, DeMarco S, FitzGerald GA. Marked Interindividual Variability in the Response to Selective Inhibitors of Cyclooxygenase-2., Gastroenterology  Jan;130(1):55-64 (2006).

 

Rudic RD, McNamara P, Reilly D, Grosser T, Curtis AM, Price T, Panda S, Hogenesch J, FitzGerald GA, Bioinformatic analysis of circadian gene oscillation in mouse aorta. Circulation;112(17):2716-24 (2005).

 

Pini B*, Grosser T* *[Co-Firstauthors], Lawson J, Price TS, Pack M, FitzGerald GA. Zebrafish prostaglandin E2 synthases, Arteriosclerosis, Thrombosis, and Vascular Biology; 25(2):315-320 (2005).

 

Grosser T, Yusuff S, Cheskis E, Pack M, FitzGerald GA. Developmental expression of functional cyclooxygenases in zebrafish. Proc Natl Acad Sci (USA) 99 (12): 8418-23 (2002).

 

Cheng Y, Austin S, Rocca B, Koller BH, Coffman, TM, Grosser T, Lawson JA, FitzGerald GA. Role of prostacyclin in the cardiovascular response to thromboxane A2. Science 296 (5567): 417-604 (2002).